.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The OPERA I and OPERA II phase 3 trials compared intravenous ocrelizumab with interferon beta-1a in relapsing multiple sclerosis. The trials showed a significantly lower annualized relapse rate with ocrelizumab along with fewer new or enlarging MRI lesions and fewer disability progression events. The results provided strong evidence that selective B-cell depletion can control inflammatory disease activity more effectively than a conventional interferon platform. Clinically, this helped establish anti-CD20 therapy as a major component of high-efficacy MS treatment. For HCPs, the decision to use ocrelizumab should integrate disease activity, prognostic factors, infection risk, vaccination, immunoglobulin monitoring and patient preference. The study also highlights the importance of distinguishing relapsing inflammatory disease from later progressive phenotypes when selecting treatment. Although ocrelizumab is highly effective, it is not a cure and requires ongoing monitoring. The findings remain central to modern MS practice and align with IANCON's emphasis on evidence-based, disease-modifying treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The OPERA I and OPERA II phase 3 trials compared intravenous ocrelizumab with interferon beta-1a in relapsing multiple sclerosis. The trials showed a significantly lower annualized relapse rate with ocrelizumab along with fewer new or enlarging MRI lesions and fewer disability progression events. The results provided strong evidence that selective B-cell depletion can control inflammatory disease activity more effectively than a conventional interferon platform. Clinically, this helped establish anti-CD20 therapy as a major component of high-efficacy MS treatment. For HCPs, the decision to use ocrelizumab should integrate disease activity, prognostic factors, infection risk, vaccination, immunoglobulin monitoring and patient preference. The study also highlights the importance of distinguishing relapsing inflammatory disease from later progressive phenotypes when selecting treatment. Although ocrelizumab is highly effective, it is not a cure and requires ongoing monitoring. The findings remain central to modern MS practice and align with IANCON's emphasis on evidence-based, disease-modifying treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
